An in vitro fertilization (IVF) medication list typically includes five primary drug classes: ovarian suppressors or birth control for cycle priming, injectable gonadotropins (FSH and LH) to stimulate multiple follicle development, GnRH antagonists or agonists to prevent premature ovulation, a trigger injection (hCG or leuprolide) for final egg maturation, and progesterone and estrogen to prepare and sustain the uterine lining for embryo implantation.

Navigating an in vitro fertilization cycle involves managing multiple specialized prescription drugs delivered through injections, oral tablets, transdermal patches, and vaginal inserts across specific treatment phases.

Cycle Priming and Baseline Suppression Medications

Before starting ovarian stimulation, reproductive endocrinologists often prescribe preparatory medications to suppress natural hormonal fluctuations, rest the ovaries, and synchronize resting follicles so they respond uniformly once stimulation begins. The most frequent baseline medications include oral contraceptive pills (combined estrogen and progestin), transdermal estrogen patches, or low-dose GnRH agonists such as leuprolide acetate.

Using birth control pills or estrogen priming allows clinical teams to schedule cycles accurately and prevents a dominant follicle from emerging prematurely before stimulation injectables start. Patients typically take these baseline medications for anywhere from ten days to several weeks leading into the stimulation calendar, tapering or discontinuing them under specific clinic instructions before introducing gonadotropin injections.

Depending on individual medical history and ovarian reserve markers, some protocols skip synthetic oral contraceptives in favor of natural cycle tracking or estrogen priming in the luteal phase. Your care team determines the optimal suppression technique based on diagnostic blood panels, baseline transvaginal ultrasound imaging, and the specific IVF protocol selected for your care plan.

  • Oral contraceptive pills: Suppress pituitary gonadotropins and synchronize follicle cohort growth.
  • Transdermal estrogen patches: Used in luteal-phase priming protocols to promote even follicle recruitment.
  • Low-dose leuprolide acetate (Lupron): Downregulates natural pituitary signaling to prevent early egg recruitment.

Further reading: CDC: Contraception and birth control methods

Ovarian Stimulation Injectables: FSH and LH Gonadotropins

The core phase of an IVF cycle relies on injectable gonadotropins that stimulate the ovaries to mature multiple eggs simultaneously rather than the single egg typical of a natural menstrual cycle. These medications deliver high concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), or a balanced combination of both. Ovarian stimulation generally lasts between eight and fourteen days, during which patients self-administer subcutaneous injections each evening.

Recombinant FSH medications—such as follitropin alfa (Gonal-f) and follitropin beta (Follistim AQ)—provide targeted stimulation to recruit and grow fluid-filled ovarian follicles. Highly purified menotropins, such as Menopur, contain a blend of naturally derived human menopausal gonadotropin providing equal parts FSH and LH activity. The LH component supports the production of estradiol within the developing follicles, improving overall follicle maturation in specific patient profiles.

Dosages are strictly personalized and adjusted continuously based on daily or every-other-day monitoring appointments. Clinical teams track serum estradiol levels and measure follicle diameters via transvaginal ultrasound, increasing or reducing daily units of gonadotropins to optimize follicular development while minimizing the risk of adverse ovarian reactions.

  • Follitropin alfa (Gonal-f) and follitropin beta (Follistim AQ): Recombinant FSH formulations delivered via multidose injector pens or prefilled cartridges.
  • Urofollitropin (Bravelle): Purified human-derived FSH administered subcutaneously.
  • Menotropins (Menopur): Combined human menopausal gonadotropins supplying both FSH and LH biological activity, reconstituted from powder.

Further reading: Office on Women's Health

Ovulation Suppressors: GnRH Antagonists and Downregulators

As multiple follicles grow and estradiol levels climb, the body naturally attempts to trigger ovulation by releasing a surge of luteinizing hormone. To prevent the ovaries from releasing eggs prematurely before the scheduled egg retrieval procedure, reproductive endocrinologists incorporate gonadotropin-releasing hormone (GnRH) antagonists or agonists into the stimulation protocol.

In modern antagonist protocols, medications such as ganirelix acetate or cetrorelix acetate (Cetrotide) are introduced partway through the stimulation phase—typically around day five or six, or when the lead follicle reaches a specified millimeter threshold. These daily subcutaneous injections immediately block GnRH receptors in the pituitary gland, halting any spontaneous LH surge within hours.

In traditional long-agonist protocols, leuprolide acetate is started in the cycle preceding stimulation to suppress the pituitary gland before gonadotropins begin, and continues at a reduced dose throughout stimulation. Selecting between an antagonist or agonist approach depends on ovarian reserve testing, prior cycle responses, and overall safety planning.

  • Ganirelix acetate: A ready-to-inject subcutaneous GnRH antagonist that prevents untimely luteinizing hormone surges.
  • Cetrorelix acetate (Cetrotide): A fast-acting GnRH antagonist requiring reconstitution with sterile diluent prior to administration.
  • Leuprolide acetate (Lupron): A GnRH agonist used in down-regulation protocols to establish baseline pituitary suppression.

Final Oocyte Maturation Trigger Injections

The trigger shot represents one of the most time-sensitive steps in an IVF medication schedule. Once several follicles reach mature dimensions on ultrasound and estradiol concentrations correspond with mature oocytes, a trigger injection is administered to induce meiosis, detaching the eggs from the follicle walls so they can be collected during transvaginal aspiration.

Clinics use two primary types of trigger medications: human chorionic gonadotropin (hCG) or a GnRH agonist like leuprolide acetate. Human chorionic gonadotropin—available as recombinant choriogonadotropin alfa (Ovidrel) or urinary-derived hCG (Novarel, Pregnyl)—mimics the natural LH surge. Recombinant forms are delivered via prefilled subcutaneous syringes, whereas urinary forms often require mixing and can be administered subcutaneously or intramuscularly.

For patients exhibiting high follicle counts or elevated estradiol levels, clinicians frequently utilize a GnRH agonist trigger (leuprolide) or a combined 'dual trigger' (low-dose hCG plus leuprolide). A GnRH agonist triggers a short-lived surge of natural pituitary LH and FSH, promoting egg maturation while significantly reducing the risk of developing ovarian hyperstimulation syndrome (OHSS). Egg retrieval is precisely timed to occur approximately thirty-four to thirty-six hours following the trigger injection.

  • Choriogonadotropin alfa (Ovidrel): Prefilled recombinant hCG injection designed for simple subcutaneous administration.
  • Human chorionic gonadotropin (Novarel, Pregnyl): Compounded or manufactured powder vials requiring sterile reconstitution.
  • Leuprolide acetate trigger: Non-hCG alternative used to prompt an endogenous LH surge and minimize hyperstimulation risks.

Luteal Phase Support: Progesterone and Estrogen Formulations

Following egg retrieval or during a medicated frozen embryo transfer (FET) cycle, the body requires exogenous hormonal support to prepare the endometrium for embryo implantation. Because the aspiration process and suppression medications disrupt the natural production of hormones by the corpus luteum, supplemental progesterone and estrogen are essential throughout early pregnancy development.

Progesterone transforms the uterine lining from a proliferative state to a receptive secretory state. In fresh transfer protocols, progesterone usually begins within one to two days after egg retrieval. In programmed frozen embryo transfers, estrogen tablets (oral or vaginal micronized estradiol), transdermal patches, or injectable estradiol valerate build the endometrial thickness before progesterone is introduced on a precise hourly timeline.

Progesterone options include intramuscular injections (progesterone in sesame, ethyl oleate, or olive oil), vaginal suppositories, and micronized vaginal gels (such as Endometrin or Crinone). Intramuscular injections provide stable systemic concentrations, while vaginal formulations offer concentrated local absorption in uterine tissue. Many clinics maintain luteal support until approximately the eighth to twelfth week of gestation, when the placenta assumes independent hormone production.

  • Progesterone in Oil (PIO): Daily intramuscular injection using large-gauge dispensing needles and fine administration needles.
  • Vaginal progesterone inserts and gels (Endometrin, Crinone, Prometrium): Administered several times daily for direct endometrial absorption.
  • Estradiol (Estrace, Vivelle-Dot, Delestrogen): Oral tablets, transdermal adhesive patches, or intramuscular injections to support lining growth.

Further reading: Office on Women's Health

Adjunctive and Supportive Medications Used in IVF Protocols

In addition to the core hormonal medications, reproductive endocrinologists frequently prescribe supportive pharmaceutical agents to prevent infection, reduce uterine inflammation, improve blood flow, or manage metabolic factors that influence egg quality and implantation.

Short courses of prophylactic antibiotics, such as doxycycline, azithromycin, or cephalexin, are commonly prescribed around the time of egg retrieval or embryo transfer to protect against microbial contamination during procedural instrumentation. Low-dose oral corticosteroids, such as methylprednisolone (Medrol) or dexamethasone, may be taken for a few days around the embryo transfer to calm local immune activity in the endometrium.

Other supportive therapies include low-dose aspirin (81 mg) to optimize uterine perfusion, baby aspirin or low-molecular-weight heparin (enoxaparin/Lovenox) for confirmed clotting disorders, and cabergoline to reduce vascular permeability if early signs of ovarian hyperstimulation emerge after egg retrieval.

  • Prophylactic antibiotics (Doxycycline, Azithromycin): Taken briefly before retrieval or transfer to prevent procedural infections.
  • Oral corticosteroids (Methylprednisolone, Dexamethasone): Short-course anti-inflammatory support during embryo transfer implantation windows.
  • Cabergoline: Dopamine agonist tablets prescribed post-retrieval to mitigate fluid shifts associated with ovarian hyperstimulation.
  • Low-dose aspirin and heparin: Prescribed selectively to support vascular perfusion and manage thrombophilic conditions.

Specialty Pharmacy Ordering, Storage Requirements, and Administration Safety

Most IVF medications cannot be filled at standard retail pharmacies and must be coordinated through accredited specialty fertility pharmacies. These facilities provide specialized packaging, temperature-controlled delivery, and ancillary medical supplies such as reconstitution syringes, micro-fine subcutaneous needles, intramuscular needles, alcohol prep pads, and puncture-resistant sharps disposal containers.

Correct storage is critical to maintaining medication potency. Certain medications—including unopened follitropin pens, cetrorelix vials, and specific trigger formulations—require continuous refrigeration between 36°F and 46°F (2°C to 8°C) and must not be frozen. Other medications, such as menotropins, reconstitution diluents, and progesterone in oil, should remain at controlled room temperature away from excessive light and heat.

Before beginning an injection cycle, verify that all ordered units, milligram concentrations, and injection supplies match your clinic's protocol sheet exactly. Label all opened multidose pens with the date of first puncture, as manufacturer stability guidelines typically require discarding opened pens within twenty-eight days. Establishing a clean, dedicated workspace and organizing supplies by administration time helps prevent missed doses or timing errors.

  • Refrigerated medications: Inspect shipping cold packs upon delivery and transfer designated vials and pens into refrigeration promptly.
  • Room-temperature storage: Keep oil-based injectables and dry powder vials in a temperature-stable, dry drawer away from sunlight.
  • Sharps safety: Dispose of used needles, glass ampoules, and prefilled syringes directly into an FDA-cleared sharps container without recapping.

Frequently asked questions

What is the difference between subcutaneous and intramuscular IVF injections?

Subcutaneous injections use short, thin needles to deliver medication into the fatty tissue layer just beneath the skin, commonly on the abdomen or upper thigh, which is typical for gonadotropins and GnRH antagonists. Intramuscular injections use longer needles to deliver medication directly into muscle tissue, most commonly the upper outer quadrant of the buttocks, which is the standard route for progesterone in oil and select trigger shots.

Why must the IVF trigger shot be taken at an exact minute?

The trigger injection initiates final oocyte maturation and detaches the eggs from the follicular walls over a precise biological timeline. If taken too early or too late, the eggs may either ovulate spontaneously before the procedure or remain too immature to be successfully retrieved during the scheduled egg collection.

What should I do if I miss an IVF medication dose?

If an injection or oral medication is missed or delayed, contact your fertility clinic's on-call nursing coordinator immediately before taking an extra dose. Your care team will review your specific protocol, bloodwork, and ultrasound timeline to determine whether to take the dose late, adjust your next administration, or modify your monitoring schedule.

Are brand-name and compounded IVF medications interchangeable?

Brand-name manufactured fertility drugs and compounded alternatives may contain identical active ingredients, but formulations, diluent volumes, and absorption rates can vary. Any change between commercial formulations, generic equivalents, or compounded preparations must be explicitly authorized and dosed by your treating reproductive endocrinologist.

Your next step

Review your printed IVF medication protocol with your clinical coordinator and confirm delivery dates, storage requirements, and needle supplies with your specialty pharmacy at least two weeks before your cycle start date.